298 related articles for article (PubMed ID: 25846551)
1. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
4. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
Jernigan AM; Mahdi H; Rose PG
Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
6. Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
Arikan SK; Kasap B; Yetimalar H; Yildiz A; Sakarya DK; Tatar S
Asian Pac J Cancer Prev; 2014; 15(15):6087-94. PubMed ID: 25124578
[TBL] [Abstract][Full Text] [Related]
7. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
9. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
[TBL] [Abstract][Full Text] [Related]
10. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
Pradjatmo H; Pradjatmo H
Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
[TBL] [Abstract][Full Text] [Related]
11. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
12. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
[TBL] [Abstract][Full Text] [Related]
13. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact.
Iborra S; Hirschfeld M; Jaeger M; Zur Hausen A; Braicu I; Sehouli J; Gitsch G; Stickeler E
Int J Gynecol Cancer; 2013 Jul; 23(6):990-6. PubMed ID: 23748175
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
15. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
[TBL] [Abstract][Full Text] [Related]
19. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
20. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]